Latest News for: tp53

Edit

High Concordance Between Immunohistochemistry (IHC) and Next Generation Sequencing (NGS) for Determining TP53 Mutation Status in Endometrial Cancer (EC): A Post Hoc Analysis of the ENGOT EN5/GOG 3055/SIENDO Study (SGO 2025, Poster Presentation) (Karyopharm Therapeutics Inc)

Public Technologies 31 Mar 2025
TP53 is a well-recognized prognostic marker for EC1. • Approximately half of advanced/recurrent EC tumors are TP53 wild-type (wt)2,3 ... Progression-free Survival of Patients with TP53 Wild-Type EC ... TP53 Mutations Observed.
Edit

Long term safety and efficacy of selinexor maintenance treatment in patients with TP53 wild type advanced or recurrent endometrial cancer: follow up subgroup analysis of the ENGOT EN5/GOG 3055/SIENDO study (SGO 2025, Oral Presentation) (Karyopharm Therapeutics Inc)

Public Technologies 31 Mar 2025
Long-term safety and efficacy of selinexor maintenance treatment in patients with TP53 wild-type advanced or recurrent endometrial cancer ... • TP53 is a well-recognized prognostic ... • TP53 mutation status.
  • 1
×